DIARRHEA and MYELOSUPPRESSION (Camptosar).
SEVERE NEUTROPENIA and SEVERE DIARRHEA (Onivyde)
See full prescribing information for complete boxed warnings.
- TRADE NAMES: Camptosar (Pfizer); Onivyde (Merrimack)
- INDICATIONS: Metastatic colorectal carcinoma (Camptosar); metastatic adenocarcinoma of the pancreas (Onivyde - in combination with fluorouracil and leucovorin). Advanced pancreatic cancer in combination with oxaliplatin/fluorouracil/leucovorin (FOLFIRINOX or FOLFOXIRI). Used in combination with fluorouracil and leucovorin (FOLFIRI) for treatment of advanced-stage and metastatic colorectal cancer
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Topoisomerase 1 inhibitor
- HALF-LIFE: 6–10 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aprepitant, Atazanavir, Bevacizumab, Itraconazole, Ketoconazole, Lapatinib, Safinamide, Sorafenib, St John's Wort, Strong CYP3A4 inhibitors, Voriconazole
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Page last updated 08/07/2024
